论文部分内容阅读
卵巢癌是具有高度侵袭性的恶性肿瘤,病死率居女性生殖系统肿瘤首位。约70%的患者就诊时已属晚期,晚期卵巢癌患者的5年存活率仅为20%[1,2]。故早发现、早治疗对于改善卵巢癌患者预后尤为重要。目前血清人附睾蛋白4(human epididymis protein 4,HE4)已作为卵巢癌诊断常用的肿瘤标志物应用于临床,但其在体液中的研究国
Ovarian cancer is a highly aggressive malignant tumor with the highest mortality rate among the female genital system tumors. Approximately 70% of patients have been treated late, and 5-year survival rate of patients with advanced ovarian cancer is only 20% [1,2]. So early detection and early treatment for the prognosis of patients with ovarian cancer is particularly important. At present, human epididymis protein 4 (HE4) has been used clinically as a tumor marker commonly used in the diagnosis of ovarian cancer, but its research in body fluids